Global Biodefense Market 2017 - 2021; New Report Launched

DrugPipeline.net has announced the addition of “Global Biodefense Market 2017 - 2021” research report to their website www.DrugPipeline.net

Logo

Bangalore, India -- (SBWire) -- 01/17/2018 --Biodefense is the use of medical measures to protect people against bioterrorism. It mainly applies to two different target populations, namely military combatant (troops in the field) and civilian non-combatant. The protection of food supplies and water are often considered a critical part of biodefense. Owing to the increasing threat of terrorism and bioterrorism, the risk posed by exposure to biological agents that can be used as biological weapons must be evaluated. Biological agents used in warfare may prove to be more potent than conventional weapons. In the last century, the developments made in biochemistry and biotechnology have simplified the production of such weapons.

Genetic engineering can be used to create new pathogens by manipulating genes, thereby giving rise to a whole new generation of genetically modified bioweapons. Factors such as ease of production, availability of technical know-how, and the extensive accessibility of biological agents have further led to the threat of biological weapons.

Report forecast the global biodefense market to grow at a CAGR of 5.41% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global biodefense market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of biodefense.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Global Biodefense market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Altimmune
- Bavarian Nordic
- DynPort Vaccine Company (DVC)
- Emergent BioSolutions

Other prominent vendors
- Acambis
- Achaogen
- Cleveland BioLabs
- Elusys Therapeutics

Market driver
- Growing threat of bioterrorism
- For a full, detailed list, view our report

Market challenge
- Lack of information about bioengineered organisms attack
- For a full, detailed list, view our report

Market trend
- Government initiatives
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?

Spanning over 88 pages "Global Biodefense Market 2017 - 2021" report covers Executive Summary, Scope Of The Report, Research Methodology, Introduction, Market Landscape, Five Forces Analysis, Market Segmentation By Application, Regional Landscape, Decision Framework, Drivers And Challenges, Market Trends, Vendor Landscape, Appendix.

For more information Visit at: https://www.drugpipeline.net/technavio/global-biodefense-market-2017-2021

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Global Dengue Vaccine Market 2017-2021 - Visit at - https://www.drugpipeline.net/technavio/global-dengue-vaccine-market-2017-2021

Global Peripheral Intravenous (IV) Catheter Market 2017-2021 - Visit at - https://www.drugpipeline.net/technavio/global-peripheral-intravenous-iv-catheter-market-2017-2021

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

Media Relations Contact

Sudeep Chakravarty
Director - Operations
DrugPipeline.net
302-703-9904
https://www.drugpipeline.net/technavio/global-biodefense-market-2017-2021

View this press release online at: http://rwire.com/916862